Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Medtronic
Baxter
Johnson and Johnson
Mallinckrodt

Last Updated: January 16, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Ipatasertib


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Ipatasertib?

Ipatasertib is an investigational drug.

There have been 48 clinical trials for Ipatasertib. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2020.

The most common disease conditions in clinical trials are Breast Neoplasms, Triple Negative Breast Neoplasms, and Prostatic Neoplasms. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and National Cancer Institute (NCI).

There are one hundred and sixty-seven US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Ipatasertib
TitleSponsorPhase
Pembrolizumab Alone or in Combination With Ipatasertib for the Treatment of Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and NeckNational Cancer Institute (NCI)Phase 2
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Stage III-IVB Head and Neck CancerNational Cancer Institute (NCI)Phase 1
A Study of Targeted Agents With Atezolizumab for Patients With Recurrent or Persistent Endometrial CancerFoundation MedicinePhase 1/Phase 2

See all Ipatasertib clinical trials

Clinical Trial Summary for Ipatasertib

Top disease conditions for Ipatasertib
Top clinical trial sponsors for Ipatasertib

See all Ipatasertib clinical trials

US Patents for Ipatasertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ipatasertib ⤷  Sign up for a Free Trial Substituted thiohydantoin derivatives as androgen receptor antagonists Janssen Pharmaceutica NV (Beerse, BE) ⤷  Sign up for a Free Trial
Ipatasertib ⤷  Sign up for a Free Trial Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity The University of North Carolina at Chapel Hill (Chapel Hill, NC) ⤷  Sign up for a Free Trial
Ipatasertib ⤷  Sign up for a Free Trial Treatment of ophthalmic conditions by selectively removing senescent cells from the eye Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN) ⤷  Sign up for a Free Trial
Ipatasertib ⤷  Sign up for a Free Trial Benzimidazole derivatives as bromodomain inhibitors Gilead Sciences, Inc. (Foster City, CA) ⤷  Sign up for a Free Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ipatasertib

Drugname Country Document Number Estimated Expiration Related US Patent
Ipatasertib Argentina AR107432 2036-01-11 ⤷  Sign up for a Free Trial
Ipatasertib Australia AU2017207268 2036-01-11 ⤷  Sign up for a Free Trial
Ipatasertib Australia AU2019203280 2036-01-11 ⤷  Sign up for a Free Trial
Ipatasertib Australia AU2021201018 2036-01-11 ⤷  Sign up for a Free Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Medtronic
Baxter
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.